48O - CC-122, a Novel Cereblon-Modulating Agent, in Combination With Obinutuzumab (GA101) in Patients With Relapsed and Refractory (R/R) B-cell Non-Hodgk...

Date 05 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Proffered Paper Session 1
Topics Lymphomas
Cancer Immunology and Immunotherapy
Haematologic Malignancies
Presenter Jean-Marie Michot
Citation Annals of Oncology (2018) 29 (suppl_3): iii7-iii9. 10.1093/annonc/mdy048
Authors J. Michot1, R. Bouabdallah2, J.K. Doorduijn3, U. Vitolo4, M.J. Kersten5, A. Chiappella4, P.L. Zinzani6, M. Pourdehnad7, Z. Nikolova8, V. Ribrag9
  • 1Institut Gustave Roussy, 94 805 - - Villejuif/FR
  • 2Institute Paoli Calmettes, Marseille/FR
  • 3Erasmus MC Cancer Institute, Rotterdam, Netherlands, on behalf of the Lunenburg Lymphoma Phase I/II Consortium (LLPC), Rotterdam/NL
  • 4Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino/IT
  • 5Academic Medical Center, Amsterdam, Netherlands; on behalf of the Lunenburg Lymphoma Phase I/II Consortium (LLPC), Amsterdam/NL
  • 6Institute of Hematology "Seràgnoli," University of Bologna, Bologna/IT
  • 7Celgene Corporation, San Francisco/US
  • 8Celgene Institute for Translational Research Europe, Sevilla/ES
  • 9Institut Gustave Roussy, Villejuif/FR

Abstract

Patients (pts) with NHL experiencing early relapse (ER) within two years of initial diagnosis and those double refractory (DR) to both rituximab and chemotherapy have particularly poor outcomes (Casulo et al JCO 2015; Gopal et al. NEJM 2014). Preliminary results from CC-122-NHL-001, the first study of CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (G), showed promising response rates in pts with R/R B-cell NHL (Michot et al Blood 2016). Herein, we report updated results for safety and efficacy from CC-122-NHL-001 (NCT02417285) with further 12 months follow up.